Short answer
Johnson & Johnson (JNJ) filed an 8-K current report with the SEC on October 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 fiscal 2026 sales and earnings announcement for quarter ended September 27, 2026.
Johnson & Johnson 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 fiscal 2026 sales and earnings announcement for quarter ended September 27, 2026
- Investor-relevant financial details contained in attached Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 sales $25.4B, up 5.9%, with operational growth 6.0%, led by Innovative Medicine growth of 7.9%
- GAAP EPS $0.09 versus $2.12, reflecting special charges tied to talc litigation, Firefly Bio, and Sail Biomedicines
- Adjusted EPS $2.59, down 7.5%, while estimated free cash flow reached approximately $15.1B year-to-date
- 2026 reported-sales guidance raised to $101.0B-$101.4B, midpoint $101.2B, representing 7.4% growth
- Adjusted EPS guidance increased $0.06 to $11.05-$11.15, midpoint $11.10, representing 2.9% growth
Item EX-99.2 · Exhibit EX-99.2
- Q3 worldwide sales $25,399M, up 5.9%, with operational growth 6.0% and U.S. growth 9.1%
- Innovative Medicine sales $16,757M, up 7.7%, led by Oncology growth 16.4% and Tremfya growth 68.3%
- MedTech sales $8,642M, up 2.5%, with cardiovascular growth 4.3% and Shockwave growth 16.8%
- Reported Q3 net earnings fell 95.9% to $210M, or $0.09 diluted EPS, driven by $5,519M litigation-related charges
- Adjusted Q3 EPS $2.59, down 7.5%, while adjusted net earnings declined 6.8% to $6,339M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Johnson & Johnson 8-K filings
Get the next JNJ 8-K as it lands
Follow JNJ for push alerts, or ask the research agent what this filing means.